Is Apple eyeing healthcare AI? Big money seems to think so

Dave Pearson | | Health Exec | Economics
iMac

International investment firm Morgan Stanley believes odds are strong that Apple will become a major player in healthcare AI, according to an article published Sept. 16 in AppleInsider.

“Morgan Stanley reckons the value-based model could be a monetization method for Apple’s own efforts,” reports AppleInsider writer Malcolm Owen, working from a note to investors received by AppleInsider about Morgan Stanley’s recent Global Healthcare Conference.

Apple is “rapidly expanding the amount of data consumers can aggregate into [its] Health app,” the note advises. “This creates a greenfield opportunity for Apple to deploy its advanced silicon and AI capabilities across these data sets.”

Read the whole thing:

Apple’s future healthcare market moves will rely heavily on AI analysis

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

HHS employees offered two months of pay to quit their jobs
Walgreens $10B private equity buyout financed by 83% debt
Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.